ArticleBiochemical genetics2026
JHDM1D-AS1 Facilitates Progression of Colorectal Cancer via the miR-193b-3p/HPRT1 Axis.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a critical global health challenge and ranks third among commonly diagnosed malignancies worldwide. As a cancer related long-noncoding RNA (lncRNA), Jumonji C domain containing histone demethylase 1 homolog D antisense 1 (JHDM1D-AS1) is analyzed to be differentially expressed in CRC samples according to bioinformatics analysis. This study aimed to further explore its effects on CRC cellular process and tumor growth as well as the related mechanisms. Quantitative polymerase chain reaction (RT-qPCR) was utilized to assess expression levels of JHDM1D-AS1 and its downstream molecules in CRC tissues and cells. Functional assays, including colony formation, wound healing, and Transwell assays, were performed to evaluate cellular processes such as proliferation, migration, and invasion. In vivo xenograft and metastasis models were established to examine tumor growth and liver metastasis. The subcellular distribution of JHDM1D-AS1 in CRC cells was measured using fluorescence in situ hybridization (FISH). RNA pulldown and luciferase reporter assays were conducted to confirm molecular interactions. HPRT1 protein expression was quantified using Western blotting. JHDM1D-AS1 is significantly upregulated in CRC cells. Knockdown of JHDM1D-AS1 suppresses CRC cell proliferation, migration, and invasion as well as xenograft tumor growth. JHDM1D-AS1 interacts with miR-193b-3p to regulate HPRT1 expression. MiR-193b-3p targets and downregulates HPRT1. Overexpression of HPRT1 reverses the suppressive effects caused by JHDM1D-AS1 depletion on CRC cell malignancy. In conclusion, JHDM1D-AS1 promotes CRC cell proliferation, metastasis, invasion and tumor development by upregulating HPRT1 expression via miR-193b-3p.
Indexed as
Identifiers
41296141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.